Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,497,160
  • Shares Outstanding, K 107,093
  • Annual Sales, $ 509,340 K
  • Annual Income, $ -207,040 K
  • 60-Month Beta 0.41
  • Price/Sales 3.07
  • Price/Cash Flow N/A
  • Price/Book 4.31
Trade NVCR with:

Options Overview Details

View History
  • Implied Volatility 113.38% ( +7.53%)
  • Historical Volatility 61.54%
  • IV Percentile 90%
  • IV Rank 66.87%
  • IV High 146.55% on 08/18/23
  • IV Low 46.44% on 09/14/23
  • Put/Call Vol Ratio 0.35
  • Today's Volume 677
  • Volume Avg (30-Day) 833
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 34,347
  • Open Int (30-Day) 37,307

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 5
  • High Estimate -0.36
  • Low Estimate -0.52
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.81 +0.07%
on 03/18/24
18.04 -23.39%
on 03/08/24
-2.32 (-14.37%)
since 02/16/24
3-Month
11.92 +15.94%
on 01/17/24
18.04 -23.39%
on 03/08/24
+0.42 (+3.13%)
since 12/18/23
52-Week
10.87 +27.14%
on 11/13/23
83.60 -83.47%
on 05/16/23
-43.25 (-75.78%)
since 03/17/23

Most Recent Stories

More News
NovoCure (NVCR) Q4 2023 Earnings Call Transcript

NVCR earnings call for the period ending December 31, 2023.

NVCR : 13.82 (-1.14%)
NovoCure: Q4 Earnings Snapshot

NovoCure: Q4 Earnings Snapshot

NVCR : 13.82 (-1.14%)
Is Novocure Stock a Buy?

The stock isn't far from its 52-week low.

NVCR : 13.82 (-1.14%)
Why Novocure Stock Was Sick Today

Investors weren't particularly pleased with the company's third-quarter performance.

NVCR : 13.82 (-1.14%)
NovoCure (NVCR) Q3 2023 Earnings Call Transcript

NVCR earnings call for the period ending September 30, 2023.

NVCR : 13.82 (-1.14%)
NovoCure: Q3 Earnings Snapshot

NovoCure: Q3 Earnings Snapshot

NVCR : 13.82 (-1.14%)
3 Things About NovoCure That Smart Investors Know

Its cancer-treating device is struggling to find its market.

NVCR : 13.82 (-1.14%)
Down 31% in 1 Day, What's Next for NovoCure Stock?

It's entering a risky period, but it could persevere.

NVCR : 13.82 (-1.14%)
Why Novocure Stock Fell 24.4% This Week

Novocure announced a disappointing outcome from a phase 3 clinical trial for a key cancer treatment.

NVCR : 13.82 (-1.14%)
Is NovoCure's Stock Headed for a Free Fall?

It can be hard to find a reason to remain bullish on NovoCure.

NVCR : 13.82 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 14.66
2nd Resistance Point 14.49
1st Resistance Point 14.15
Last Price 13.82
1st Support Level 13.65
2nd Support Level 13.48
3rd Support Level 13.14

See More

52-Week High 83.60
Fibonacci 61.8% 55.82
Fibonacci 50% 47.24
Fibonacci 38.2% 38.65
Last Price 13.82
52-Week Low 10.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar